These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8930782)

  • 1. Effects of befloxatone, a reversible selective monoamine oxidase-A inhibitor, on psychomotor function and memory in healthy subjects.
    Warot D; Berlin I; Patat A; Durrieu G; Zieleniuk I; Puech AJ
    J Clin Pharmacol; 1996 Oct; 36(10):942-50. PubMed ID: 8930782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive performance in elderly subjects after a single dose of befloxatone, a new reversible selective monoamine oxidase A inhibitor.
    Rosenzweig P; Patat A; Zieleniuk I; Cimarosti I; Allain H; Gandon JM
    Clin Pharmacol Ther; 1998 Aug; 64(2):211-22. PubMed ID: 9728902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers.
    Patat A; le Coz F; Dubruc C; Gandon JM; Durrieu G; Cimarosti I; Jezequel S; Curet O; Zieleniuk I; Allain H; Rosenzweig P
    J Clin Pharmacol; 1996 Mar; 36(3):216-29. PubMed ID: 8690815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.
    Caille D; Bergis OE; Fankhauser C; Gardes A; Adam R; Charieras T; Grosset A; Rovei V; Jarreau FX
    J Pharmacol Exp Ther; 1996 Apr; 277(1):265-77. PubMed ID: 8613929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of milnacipran in young and elderly volunteers.
    Hindmarch I; Rigney U; Stanley N; Briley M
    Br J Clin Pharmacol; 2000 Feb; 49(2):118-25. PubMed ID: 10671905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects.
    Patat A; Berlin I; Durrieu G; Armand P; Fitoussi S; Molinier P; Caille P
    J Clin Pharmacol; 1995 Jun; 35(6):633-43. PubMed ID: 7665725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical pharmacology of befloxatone (MD370503), a new potent reversible MAO-A inhibitor.
    Rovei V; Caille D; Curet O; Ego D; Jarreau FX
    J Neural Transm Suppl; 1994; 41():339-47. PubMed ID: 7931248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of befloxatone: a brief review.
    Rosenzweig P; Patat A; Curet O; Durrieu G; Dubruc C; Zieleniuk I; Legangneux E
    J Affect Disord; 1998 Dec; 51(3):305-12. PubMed ID: 10333984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of moclobemide on psychomotor performance and cognitive function.
    Fairweather DB; Kerr JS; Hindmarch I
    Int Clin Psychopharmacol; 1993; 8(1):43-7. PubMed ID: 8473720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of cyproheptadine and DL carnitine on psychomotor performance and memory in healthy volunteers.
    Hakkou F; Jaouen C; Iraki L
    Fundam Clin Pharmacol; 1990; 4(2):191-200. PubMed ID: 2351368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile.
    Curet O; Damoiseau G; Aubin N; Sontag N; Rovei V; Jarreau FX
    J Pharmacol Exp Ther; 1996 Apr; 277(1):253-64. PubMed ID: 8613928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoelectroencephalographic profile of befloxatone, a new reversible MAO-A inhibitor, in healthy subjects.
    Luthringer R; Dago KT; Patat A; Caille P; Curet O; Durieu G; Rinaudo G; Toussaint M; Granier LA; Macher JP
    Neuropsychobiology; 1996; 34(2):98-105. PubMed ID: 8904739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.
    Berlin I; Zimmer R; Thiede HM; Payan C; Hergueta T; Robin L; Puech AJ
    Br J Clin Pharmacol; 1990 Dec; 30(6):805-16. PubMed ID: 1705137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of amnestic, psychotomimetic or impairing effect on psychomotor performance of eliprodil, a new NMDA antagonist.
    Patat A; Molinier P; Hergueta T; Brohier S; Zieleniuk I; Danjou P; Warot D; Puech A
    Int Clin Psychopharmacol; 1994 Sep; 9(3):155-62. PubMed ID: 7814824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical profile of befloxatone, a new reversible MAO-A inhibitor.
    Curet O; Damoiseau-Ovens G; Sauvage C; Sontag N; Avenet P; Depoortere H; Caille D; Bergis O; Scatton B
    J Affect Disord; 1998 Dec; 51(3):287-303. PubMed ID: 10333983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Befloxatone (Synthelabo).
    Emilien G
    IDrugs; 1999 Mar; 2(3):247-53. PubMed ID: 16160936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power to dissociate sedative-related impairments from memory dysfunctions.
    Wezenberg E; Sabbe BG; Hulstijn W; Ruigt GS; Verkes RJ
    J Psychopharmacol; 2007 Aug; 21(6):579-87. PubMed ID: 17092974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preliminary investigation on the acute pharmacodynamic effects of hypericum on cognitive and psychomotor performance.
    Timoshanko A; Stough C; Vitetta L; Nathan PJ
    Behav Pharmacol; 2001 Dec; 12(8):635-40. PubMed ID: 11856901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the interaction between a partial agonist and a full agonist of benzodiazepine receptors, based on psychomotor performance and memory, in healthy volunteers.
    Patat A; Perault MC; Vandel B; Danjou P; Brohier S; Zieleniuk I; Rosenzweig P
    J Psychopharmacol; 1995 Jan; 9(2):91-101. PubMed ID: 22298734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers.
    Hallam KT; Olver JS; McGrath C; Norman TR
    Hum Psychopharmacol; 2003 Dec; 18(8):619-25. PubMed ID: 14696021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.